[Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a report of 12 patients].

Abstract

OBJECTIVE:

To retrospectively review the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelomonocytic leukemia (CMML).

METHODS:

The engraftment, graft versus host disease (GVHD), infection, relapse and survival of 12 CMML patients received allo-HSCT were observed. The clinical outcome of allo-HSCT for CMML was analyzed.

RESULTS:

Twelve (7 males and 5 females) CMML patients with a median age of 39 years old received allo-HSCT including 7 from HLA-matched sibling and 5 from haploidentical related donors. All 12 patients achieved engraftment. The median time of neutrophil engraftment and platelet engraftment were 15 (11 - 20) days and 13 (11 - 18) days, respectively. 4 patients occurred acute GVHD, and 3 occurred chronic GVHD. After the median follow-up of 17.5 months (12 - 32 months), the overall survival, disease free survival and relapse rate were 66.7%, 66.7%, and 16.7%, respectively.

CONCLUSION:

Allo-HSCT can improve the survival of patients with CMML, and is a effective therapy for CMML.

• Authors: Yu-qian Sun, Lan-ping Xu, Dai-hong Liu, Xiao-hui Zhang, Wei Han, Huan Chen, Feng-rong Wang, Jing-zhi Wang, Yu Wang, Yu-hong Chen, Kai-yan Liu, Xiao-jun Huang
• Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (Zhonghua Xue Ye Xue Za Zhi) Vol. 34 Issue 2 Pg. 113-6 (Feb 2013) ISSN: 0253-2727 [Print] China
• PMID: 23611216 (Publication Type: English Abstract, Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)

Topics

• Adolescent
• Adult
• Child
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (therapy)
• Male
• Middle Aged
• Retrospective Studies
• Survival Rate
• Transplantation, Homologous
• Young Adult